Bbva Compass Bancshares Inc. grew its stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 21.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,257 shares of the biotechnology company’s stock after purchasing an additional 3,227 shares during the quarter. Bbva Compass Bancshares Inc. owned approximately 0.12% of Anika Therapeutics worth $1,059,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ANIK. Thomson Horstmann & Bryant Inc. purchased a new stake in shares of Anika Therapeutics during the second quarter valued at approximately $11,345,000. Bank of New York Mellon Corp boosted its stake in shares of Anika Therapeutics by 76.8% during the second quarter. Bank of New York Mellon Corp now owns 490,433 shares of the biotechnology company’s stock valued at $24,199,000 after purchasing an additional 213,055 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Anika Therapeutics by 13.8% during the second quarter. Dimensional Fund Advisors LP now owns 878,006 shares of the biotechnology company’s stock valued at $43,321,000 after purchasing an additional 106,307 shares during the period. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Anika Therapeutics by 6.6% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,423,593 shares of the biotechnology company’s stock valued at $70,241,000 after purchasing an additional 88,418 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Anika Therapeutics by 51.7% during the first quarter. Renaissance Technologies LLC now owns 253,100 shares of the biotechnology company’s stock valued at $10,995,000 after purchasing an additional 86,300 shares during the period. 84.29% of the stock is owned by hedge funds and other institutional investors.

Anika Therapeutics Inc. (NASDAQ:ANIK) traded up $0.27 during trading hours on Friday, hitting $53.76. The stock had a trading volume of 65,155 shares, compared to its average volume of 82,321. The stock has a market capitalization of $788.22 million, a price-to-earnings ratio of 25.11, a PEG ratio of 2.81 and a beta of 1.47. Anika Therapeutics Inc. has a 52-week low of $41.40 and a 52-week high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.05. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The company had revenue of $27.18 million during the quarter, compared to analyst estimates of $27.44 million. During the same quarter last year, the firm posted $0.59 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. sell-side analysts forecast that Anika Therapeutics Inc. will post 1.9 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on ANIK shares. Barrington Research increased their price objective on Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 8th. Finally, Zacks Investment Research raised Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 2nd.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/04/bbva-compass-bancshares-inc-has-1-06-million-stake-in-anika-therapeutics-inc-anik.html.

In related news, CEO Charles H. Sherwood sold 7,124 shares of the firm’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $60.08, for a total value of $428,009.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Charles H. Sherwood sold 3,293 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $60.04, for a total value of $197,711.72. The disclosure for this sale can be found here. Insiders sold 38,636 shares of company stock valued at $2,320,435 in the last ninety days. 6.57% of the stock is currently owned by insiders.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.